

Technology Appraisal Committee A Interests Register

Topic: Ribociclib with an aromatase inhibitor for adjuvant treatment of hormone receptor-positive, HER2-negative early breast cancer [ID6153]

Publication Date: 6th August 2025

Name	Role with NICE	Type of interest	Description of interest	Interest declared	Comments
Professor David Cameron	Clinical Expert	Indirect - Financial	<p>Professor Cameron has done advisory boards and speaking engagements with Novartis relating to the drug ribociclib for advanced breast cancer. He was also on the steering committee of one of the trials, Monaleesa-2. Any payments go to his institution, none to him personally.</p> <p>Professor Cameron has done other advisory boards and speaking engagements with Novartis for other agents and has had research funding relating to other Novartis agents. Any payments are to his institution, or for research funding sometimes another institution, none to him. Agents involved are Letrozole, Zoledronate, Everolimus. Everolimus is the only one still active in the form of research funding to</p>	<p>03/06/2025</p> <p>01/04/2025</p>	It was agreed that Professor Cameron's declaration would not prevent him from providing expert advice to the committee.

Name	Role with NICE	Type of interest	Description of interest	Interest declared	Comments
			<p>support an ongoing French study, UNIRAD.</p> <p>He also had academic funding and done speaking engagements and advisory board work for GSK's compound Lapatinib, which is now owned by Novartis.</p>		
Doctor Michal Sladkowski	Clinical Expert	Direct - Financial	Novartis £650 breast cancer educational event for NMP (not product related)	03/06/2025 01/04/2025	It was agreed that Doctor Sladkowski's declaration would not prevent him from providing expert advice to the committee.
James Fotheringham	TAC Member	Indirect - Financial	James performed a systematic review for AstraZeneca in the disease area of hypertension - paid to my employer	03/06/2025	It was agreed that James' declaration would not prevent him from participating in discussions on this appraisal.
Prithwiraj Das	TAC Member	Non-Financial Professional	Prithwiraj worked for comparator manufacturer AZ until February 2022.	03/06/2025	It was agreed that Prithwiraj's declaration would not prevent him from participating in discussions on this appraisal.

